Mounjaro
Largest revenue line; Q2 2026 revenue $9.94B.
The numbers
What it is
Tirzepatide injection for type 2 diabetes, a dual GIP and GLP-1 receptor agonist. It is Lilly's largest product and is also sold outside the US.
Why it matters to the stock. Mounjaro's volume and price set the tone for the whole company, and it is the main read-through for Lilly's incretin franchise and rival GLP-1 pricing.
News
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Michigan Supreme Court reverses appeals ruling in Lilly insulin pricing case
Lilly's quarterly report says the Michigan Supreme Court in July 2026 reversed a Michigan Court of Appeals decision in the insulin pricing litigation.
Lilly's Q1 2026 revenue rose 56%; full-year guidance raised
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56%, mainly from volume growth partly offset by lower realized prices.
Lilly's Q4 2025 revenue rose 43%; 2026 guidance set at $80B-$83B
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, driven by volume growth for Mounjaro and Zepbound.